[Form 4] Aldeyra Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Aldeyra Therapeutics officer and director Michael Alfieri reported a non-derivative purchase of 2,500 shares of Aldeyra common stock on 08/13/2025 at a reported price of $5.30 per share. Following the transaction he beneficially owns 2,500 shares directly. The Form 4 was signed on 08/15/2025.

Positive

• Officer purchase disclosed: Michael Alfieri reported a direct acquisition of 2,500 shares, showing insider participation in equity ownership
• Full disclosure provided: Transaction date, price ($5.30), and post-transaction ownership are explicitly reported

Negative

• None.

Insights

Financial Analyst

TL;DR: Insider purchase of 2,500 shares by a senior executive is a modest positive signal but not materially transformative.

The reported open-market purchase of 2,500 shares at $5.30 by the Principal Financial Officer and director indicates a direct personal purchase of equity. The size is small relative to typical company float and therefore unlikely to alter valuation or control dynamics. This disclosure is routine under Section 16 and provides transparency on insider holdings and trades.

Corporate Governance Expert

TL;DR: Filing is compliant and timely; purchase disclosure shows standard insider reporting practices.

The Form 4 lists the reporting person, relationship to the issuer as officer and director, transaction date, price and post-transaction ownership, and is signed. It fulfills Section 16 reporting obligations and shows no complex arrangements or derivative activity. No amendments or additional explanatory notes accompany the filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Alfieri Michael

(Last) (First) (Middle)

C/O ALDEYRA THERAPEUTICS, INC.

131 HARTWELL AVENUE

(Street)

LEXINGTON MA 02421

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Aldeyra Therapeutics, Inc. [ ALDX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Principal Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/13/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/13/2025		P		2,500	A	$5.3	2,500	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Michael Alfieri	08/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did ALDX insider Michael Alfieri report on Form 4?

He reported a non-derivative purchase of 2,500 shares of Aldeyra common stock on 08/13/2025 at $5.30 per share.

How many Aldeyra shares does Michael Alfieri own after the transaction?

The Form 4 reports he beneficially owns 2,500 shares directly following the reported transaction.

When was the Form 4 for ALDX signed?

The Form 4 was signed by Michael Alfieri on 08/15/2025.

Was the transaction in ALDX a derivative or non-derivative trade?

It was a non-derivative trade (purchase of common stock).

Does the filing show any derivative activity or complex arrangements?

No. Table II is empty and there are no derivative securities or additional arrangements disclosed.